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Abstract 
Skin is the body’s first barrier against external pathogens that maintains the homeostasis of the body. Any serious 
damage to the skin could have an impact on human health and quality of life. Tissue engineering aims to improve 
the quality of damaged tissue regeneration. One of the most effective treatments for skin tissue regeneration is 
to improve angiogenesis during the healing period. Over the last decade, there has been an impressive growth of 
new potential applications for nanobiomaterials in tissue engineering. Various approaches have been developed to 
improve the rate and quality of the healing process using angiogenic nanomaterials. In this review, we focused on 
molecular mechanisms and key factors in angiogenesis, the role of nanobiomaterials in angiogenesis, and scaffold‑
based tissue engineering approaches for accelerated wound healing based on improved angiogenesis.
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Background
Wound healing is an accurate and well-orchestrated 
process in healthy individuals. Nevertheless, shortcom-
ings in the wound healing lead to more than 38 million 
patients with chronic wounds worldwide, reaching epi-
demic proportions, causing a huge economic burden 
on the healthcare systems [1, 2]. It has actually been 
described that chronic wounds can have as profound an 
impact on the quality of life as renal and cardiovascular 
disorders. In addition, mortality nowadays rivals that of 
cancer patients for some patients with chronic wounds 
[3]. Autoimmune diseases, diabetes, aging, cardiovas-
cular diseases, obesity, sensory neuropathies or consti-
tute some of the reasons that cause the aforementioned 
pathology [4]. According to the latest Global Wound Care 
Market report, the sector has reached a value of about 
20 billion dollars. Moreover, this amount is estimated to 
reach more than 25 billion dollars worldwide in 2023 [5]. 
It is therefore reasonable that adequate and well-planned 
management of chronic wounds has become important 
over the last decades in order to improve human quality 
of life and increase life expectancy.
In recent decades, various strategies have been devel-
oped for the treatment of chronic wounds. The most 
successful clinical strategy is skin autograft. Lack of 
immunogenicity is the most significant advantage of 
this method, but when the injured area exceeds more 
than 60% of the patient’s total body surface area, auto-
grafts could not cover the entire wounded site [6]. Pain, 
pigmentation disturbance and hair regeneration prob-
lems are other reported post-surgical issues related to 
the donor site [7]. Due to the limitations of this method, 
alternative strategies need to be developed to acceler-
ate the process of wound healing. In order to develop 
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process of chronic wound healing and the mechanisms 
of the most important factors affecting the process are 
needed.
Wound healing is a complex multi-step process. In 
the first step, a clot plugs the wounded site. The repair 
and regeneration of the area would then continue with 
the formation of granulation tissue due to the introduc-
tion of fibroblasts, capillaries and immune cells into the 
clot. The edge of the wound would be aggregated and the 
epidermal layer would cover the surface of the wound. 
A balance between cell activity, such as proliferation, 
migration, differentiation and apoptosis, would lead to 
the creation of multilayer skin [8–10]. In this process, 
angiogenesis plays a significant role in improving the rate 
and quality of the healing process, and therefore the key 
role of angiogenesis is central to many studies of wound 
healing. In brief, angiogenesis implies the formation of 
new capillaries from pre-existing vessels to create a com-
plex network of blood vessels [11]. Angiogenesis at the 
wound site provides more nutrition through blood flow 
and improves the healing process.
Many strategies to improve skin regeneration are 
based on stimulating and enhancing angiogenesis. In 
this regard, a promising approach is to use engineered 
structures, such as scaffolds with or without cells that can 
mimic the native tissue functionally. Such scaffolds could 
provide an appropriate microstructure similar to the 
extracellular matrix (ECM) for native cells to proliferate, 
migrate and differentiate. Various elements and factors, 
such as ions, nanoparticles and growth factors, could be 
incorporated in these structures to give them angiogenic 
properties. As an example, nanoparticles that are cur-
rently used as drug carriers could be incorporated into 
nanofibrous scaffolds that could provide a high surface/
volume ratio for cell adhesion. The attached cells would 
be exposed to the angiogenic factors [12–15]. The use of 
nanocomposite scaffolds to improve angiogenesis in the 
field of skin tissue engineering has significantly increased 
over the last decade [16]. In this paper, we will discuss 
molecular mechanisms and key factors in angiogenesis, 
the role of nanobiomaterials in angiogenesis, and scaf-
fold-based tissue engineering approaches for accelerated 
wound healing based on improved angiogenesis.
Angiogenesis in wound healing
Immediately after the accumulation of inflammatory cells 
following the injury, many angiogenic agents are secreted 
by these cells, causing the formation of new blood ves-
sels. Defects in angiogenesis at this stage may lead to 
chronic wounds due to a slow rate of healing [11, 17]. 
After the inflammatory response following the injury, sig-
nals are transmitted to the endothelial cells that stimulate 
these cells to secrete matrix metalloproteinases (MMPs) 
and some other proteases leading to degradation of the 
basement membrane [18]. This situation provides an 
opportunity for the invasion of the tip cells into the sur-
rounding matrix. The tip cells develop from the endothe-
lial cells through the notch signaling pathway and are 
responsible for invasion and germination [19]. Prolifera-
tive stem cells are originated from other endothelial cells 
in order to develop vascular lumen. At last, the adherence 
of endothelial cells, with the help of vascular endothelial 
cadherin (VE-cadherin) as the main adhesive molecules, 
inhibits the proliferation to finalize vascularization [20]. 
Pericytes surrounded by basement membranes help to 
stabilize the recently formed vessels [21]. Figure 1 shows 
the main stages of angiogenesis process.
Main factors of angiogenesis
Vascular endothelial growth factor (VEGF)
Many studies have demonstrated that the VEGF family is 
the most important stimulating factor in the angiogenesis 
process. The main role of VEGF is to stabilize the vascular 
system through the formation of new networks of blood 
vessels. VEGF also involves the development of embry-
onic vascular system [25]. VEGF-A is the main stimula-
tor of the blood vessels growth. VEGF-A is responsible 
for VEGFR2 phosphorylation, which induces endothe-
lial cell migration, proliferation and differentiation [26]. 
Growth factors, cytokines, hypoxia and hormones are 
the most important regulatory factors for VEGF-A gene 
expression [27]. VEGFR1, VEGFR2 and VEGFR3 are the 
tyrosine kinase receptors of the VEGF family. VEGF-A, 
VEGF-B and PGF are related to VEGFR1. VEGF-A also 
has an affinity to VEGFR2. The primary receptor for 
VEGF-C and VEGF-D is VEGFR3 [28].
VEGFR1 is structurally the same as VEGFR2. VEGFR1 
is responsible for the negative regulation of VEGFR2 
activities. VEGFR1 could transmit angiogenesis regu-
lation signals by phosphorylation of downstream pro-
tein through an auto-phosphorylation process [29, 30]. 
VEGFR2 has a stronger tyrosine activity compared to 
VEGFR1, which can promote the survival, proliferation 
and migration of endothelial cells in order to improve 
angiogenesis [29]. One of the most important signal-
ing pathways leading to endothelial cell proliferation is 
PLCγ/PKC/MAPK, which is induced by the binding of 
VEGF to VEGFR2 [31]. A summary of the signaling path-
ways induced by three types of VEGF receptors binding 
to their ligands is shown in Fig. 2.
Angiopoietin
Angiopoietin (ANGPT) plays a central role in the pro-
cess of angiogenesis. It also regulates the permeabil-
ity of vessels, causes vascular maturation, and keeps 
integrity and stability of the blood vessels. Survival 
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and proliferation of endothelial cells and pericytes 
are affected by levels of ANGPT [41]. Receptors of 
ANGPT, Tie1 and Tie2, were identified in 1992. Tie2 is 
the receptor for ANGPT ligands and researchers have 
recently demonstrated the regulatory effects of Tie1 
on Tie2 tyrosine kinase activity [42]. ANGPT-1 and 
ANGPT-2 were identified after the identification of 
their receptors. ANGPT-3 and ANGPT-4 were cloned 
from rodent and human sources, respectively [43]. 
Cells around the blood vessels are the primary source 
of ANGPT-1 expression. When ANGPT-1 is bound to 
its receptor (Tie2), the tyrosine kinase pathway is acti-
vated, leading to dimerization of the receptor by which 
tyrosine residues are phosphorylated. Cell viability, 
attachment, proliferation, migration and improved ves-
sel stability are the results of studies obtained by acti-
vation of Akt and protein kinase B through the P13K 
signaling pathway [44, 45]. Yuan et al. showed the par-
tial agonist/antagonist function of ANGPT-2 in Tie2 
signaling in endothelium. ANGPT-2 also plays a key 
role in the regulation of angiogenesis by activating 
Tie2. In endothelial cells, the secretion of ANGPT-2 
stimulated by growth factors, inhibits ANGPT-1/Tie2 
signaling pathway (The function of ANGPT-1 is antag-
onistic). While, ANGPT-2 could bind to integrin to 
enhance angiogenesis [46, 47]. Figure 3 shows the role 
of ANGPT-1 and ANGPT-2 in angiogenesis.
Fibroblast growth factors (FGFs)
Fibroblast growth factors (FGFs) are a large family of 
homologous peptides. Basic fibroblast growth factor 
(bFGF) is one of the most studied growth factors in can-
cer and angiogenesis studies [51]. As a result of its effects 
on endothelial cells and smooth muscle cells, bFGF 
induces angiogenesis as well as its function as a chemo-
attractant and aids in the survival and proliferation of 
epithelial cells and fibroblasts [52].
Angiogenic properties of bFGF have been investigated 
by various authors in chick embryo chorioallantoic mem-
branes (CAM) and rodent corneas [53, 54]. In addition 
to investigating the direct impact of bFGF on endothelial 
cell proliferation, Stavri et  al. investigated the potential 
for bFGF to act indirectly through the upregulation of 
VEGF expression in vascular smooth muscle cells. They 
demonstrated that bFGF could also play an indirect role 
in stimulating angiogenesis by promoting VEGF expres-
sion [55]. An in  vivo study conducted by Asahara et  al. 
investigated the synergistic effect of VEGF and bFGF on 
the rabbit hind limb ischaemia model. The findings indi-
cated a significant increase in angiogenesis when both 
growth factors were used together for treatment [56]. 
In 2007, Doi et  al. produced a gelatin hydrogel-based 
controlled release system for bFGF. The effects of sus-
tained release of bFGF on angiogenesis were evaluated 
in rabbits following removal of the femoral artery. bFGF 
Fig. 1 Main stages of angiogenesis [22–24]. A normal blood vessel (a). Angiogenic substances stimulate the angiogenesis process (b). Invasion of 
tip cells and lumen formation (c). Maturation of the new formed blood vessel (d)
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treatment rabbits showed a concentration-dependent 
increase in vascular density, tissue perfusion and arteri-
ole counts [57]. Recently, Yoo et al. have produced visible 
light-cured glycol chitosan hydrogels containing bFGF 
and EGF to accelerate the full-thickness wound healing 
process in Balb/C mice [58].
The following section discusses the common delivery 
systems used in chronic wound healing applications.
Common approaches
Common approaches to improve angiogenesis are based 
on delivery systems (usually cells, proteins and growth 
factors) [59, 60]. The main issues of these systems are the 
short half-life of angiogenic factors and poor intake [61]. 
An alternative system for long-term induction of angio-
genesis is the delivery of efficient genes to the injured 
tissue. The advantages of gene delivery systems are sig-
nificant compared to protein delivery, which includes 
long-term expression and secretion of the angiogenic 
factor at the injured site, high efficacy, lower side effects, 
and increased activity [62, 63]. As an example, Micro-
RNA-135a-3p accelerates the process of angiogenesis by 
affecting the p38 signaling pathway in diabetic rodents, 
resulting in more effective wound healing [64]. Stimu-
lating hormones, such as erythropoietin, are also used 
to improve the efficacy of the treatment [65]. Another 
approach is to use potent mesenchymal stem cells to 
enhance angiogenesis in the wound healing process [66].
Recent progress in nanobiotechnology has signifi-
cantly improved potential applications in delivery 
systems. Nanobiomaterials exhibit appropriate phys-
ico-chemical properties to be used in medicine and in 
Fig. 2 Signaling pathways induced by VEGF receptors following 
binding to their ligands [31–40]
Fig. 3 The role of ANGPT‑1, ANGPT‑2 and their receptor (Tie2) in 
angiogenesis [44, 45, 48–50]
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different fields of biology [67]. High surface/volume 
ratio, acceptable biocompatibility, loading efficiency 
and surface-modification capability are considered to 
be the most significant advantages of nanomaterials 
[68]. Based on these properties, a number of investiga-
tions have been conducted in the field of skin regen-
eration using nanomaterials in different ways. Some of 
these nanomaterials induce angiogenesis due to their 
unique physico-chemical characteristics [69, 70]. Bio-
glass nanoparticles (BG-NPs), some of metal-based 
nanoparticles, graphene-based nanomaterials and car-
bon nanotubes (CNTs) are examples of these angio-
genic nanomaterials. Angiogenic nanomaterials could 
be incorporated into engineered structures such as 
scaffolds [71]. Scaffolds could be prepared from a wide 
range of natural or synthetic biomaterials. These bio-
materials are usually biodegradable, which provide a 
slow release system for angiogenic nanomaterials to be 
released at an appropriate rate [72].
In the following sections, we will discuss appropriate 
characteristics of skin scaffolds, angiogenic nanomateri-
als and the applications of the incorporated scaffolds for 
wound healing and skin tissue engineering.
Appropriate characteristics of a skin scaffold
Mechanical properties
Scaffolds that are intended to be used for wound healing 
applications should have appropriate mechanical prop-
erties that can support cellular activities such as prolif-
eration, migration and angiogenesis, as well as to protect 
structures found in native skin such as blood vessels, lym-
phatic systems and nerve bundles [73]. For this purpose, 
the skin scaffold should have mechanical properties simi-
lar to those found in native tissue. In this regard, the val-
ues of the tensile strengths, the Young’s modulus and the 
elongation-to-break are the most important parameters 
for assessing the suitability of the mechanical properties 
of the scaffold [74]. Although these values vary depend-
ing on the region of the native tissue, but according to 
the literature, the tensile strength between 5 and 40 MPa, 
the Young’s modulus between 4.5 and 25  MPa, and the 
elongation-to-break between 35 and 120% seem to be 
appropriate for wound dressings [75, 76]. Such values 
provide sufficient mechanical support for angiogenesis 
and tissue remodeling processes during wound healing 
and also prevent the side effects of stress shielding [77]. 
Many studies have shown the excellent mechanical prop-
erties of synthetic polymers such as polycaprolactone 
(PCL), polyurethane (PU) and poly (lactic-co-glycolic 
acid) (PLGA) due to their thermal and chemical stability 
[78, 79]. These polymers could also be blended with natu-
ral polymers such as chitosan, collage and gelatin, which 
have excellent biocompatibility in order to improve their 
mechanical properties [80–82].
Porosity
In the field of skin tissue engineering, the porosity of a 
scaffold is critical to provide adequate spaces for cell 
accommodation, proliferation, migration and differentia-
tion. Porous scaffolds also facilitate the oxygenation and 
nutrition of the wounded skin through the 3D matrix 
[83]. Some studies have shown that scaffolds with 60 to 
90% porosity are suitable for wound healing applications 
as they are capable of providing the sufficient space for 
cell activity, oxygen and nutrient exchange, and the pro-
duction of a new ECM [84]. Since the increase in the 
porosity of a scaffold has a direct effect on the reduction 
of the mechanical parameters mentioned above, the bal-
ance between the porosity and the mechanical proper-
ties of the scaffold is critical [85]. In order to prevent a 
significant reduction in the mechanical properties of the 
scaffold, nanobiomaterials such as carbon nanotubes and 
ceramic or metallic nanoparticles can be used which, in 
addition to increasing the mechanical properties, also 
stimulate angiogenesis [86, 87].
Surface wettability of skin scaffolds
Wettability is one of the most significant features of the 
material’s surface. The surface hydrophilicity of skin scaf-
folds is a critical parameter that affects cell attachment, 
proliferation and differentiation [88]. The wettability 
of the scaffolds is usually determined by measuring the 
water contact angle at the surface of the scaffold [89]. 
According to other studies, moderate hydrophilic sur-
faces with a water contact angle between 30 and 70º have 
been shown to encourage cells to adhere and expand 
[90]. On the other hand, hydrophobic and highly hydro-
phobic surfaces exhibited lower cell adhesion. Pres-
ence of hydrophilic functional groups such as hydroxyl, 
esters and amides in the structure of many natural-based 
biopolymers make these biomaterials suitable to be used 
for skin tissue engineering applications [85]. Since the 
first step in angiogenesis is the attachment of cells to the 
scaffold, natural-based scaffolds incorporated with angio-
genic nanobiomaterials are suitable for enhancing angio-
genesis during the wound healing process. Hydrophilic 
wound dressings and skin scaffolds are also capable of 
providing moist environments that promote the healing 
process [91].
Water vapor transmission rate and water uptake ability
As mentioned above, in addition to providing a moist 
environment, the ideal skin scaffold or wound dressing 
should also prevent dehydration of the wound and be 
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able to remove the excessive wound exudate [92]. In this 
regard, an ideal skin scaffold should have a water absorp-
tion capacity of 100 to 800% (compared to its dry weight) 
to prevent the accumulation of fluids in order to enhance 
the formation of the new ECM [93, 94]. The accumula-
tion of wound exudate at the injured site results in the 
degradation of ECM components and involvement of the 
surrounding tissues, which causes excessive pain to the 
patient [91]. In addition, it has been shown that skin scaf-
folds with water vapor transmission values ranging from 
2000 to 2500  g/m2/day provide sufficient moisture and 
prevent the accumulation of wound exudate. Low water 
vapor transmission rates prevent gaseous exchanges 
leading to an accumulation of  CO2 that can lead to the 
acidification of the wound media. This condition could 
have a direct impact on the regeneration of the injured 
tissue by inhibiting cell proliferation during angiogen-
esis. It is also provide an appropriate environment for the 
growth of anaerobic bacteria. On the other hand, high 
water vapor transmission rates can also lead to dehydra-
tion of the wound [91, 95].
Degradation rate and release profile
In the case of biodegradable skin scaffolds, degradation 
rate and release profile are important parameters that 
should be considered. The higher degradation rate of the 
scaffold leads to the higher release rate of the incorpo-
rated bioactive factor [96]. On the other hand, the degra-
dation rate of the skin scaffold should be proportional to 
the healing rate of the wounded skin [97]. Incorporation 
of nanobiomaterials can affect the physicochemical prop-
erties of the scaffolds and therefore their degradation 
rate and release profile [98]. Other important factors that 
can directly affect these two parameters are cross-linkers 
and crosslinking procedures. Chemical crosslinkers such 
as glutaraldehyde and N-ethyl-N′-(3-(dimethylamino)
propyl) carbodiimide/N-hydroxysuccinimide (EDC/
NHS) significantly reduce the rate of degradation of a 
wide range of biopolymers in both in  vitro and in  vivo 
aquatic environments. The cross-linking time and type 
of cross-linker should therefore be optimized according 
to the type of wound and the severity of the injury [99]. 
High levels of some angiogenic nanobiomaterials, such as 
metallic- and ceramic-based nanoparticles, could induce 
dose-dependent toxicity. The incorporation of high levels 
of these nanoparticles into scaffolds with an appropriate 
rate of degradation could provide a slow-release system 
that can stimulate angiogenesis without inducing dose-
dependent toxicity [100, 101].
Protein adsorption
When the skin scaffold is placed at the injured site, it is 
immediately exposed to proteins in the body’s fluids. The 
proteins are attached to the surface of the scaffold and 
provide an adhesive surface. Albumin is the most abun-
dant protein in serum and after an injury occurs this pro-
tein is accumulated at the wound site. Subsequently, the 
absorbed albumin is replaced by fibronectin and vitron-
ectin. The protein-coated surface could induce cell adhe-
sion through membrane receptors [102]. As mentioned 
earlier, cell adhesion is the first step for angiogenesis. 
This could have a direct effect on skin scaffold biocom-
patibility [103]. Evaluation of albumin absorption can be 
an appropriate index to determine the ability of a skin 
scaffold or wound dressing to absorb proteins [85, 104].




A wide range of metal-based nanoparticles have been 
widely used as angiogenic treatments for wound healing 
and skin regeneration. Zinc oxide nanoparticles (ZnO-
NPs) have been shown to induce endothelial cell migration 
and enhance blood vessel formation by producing nitric 
oxide (NO) through the MAPK/Akt/eNOS pathway [105]. 
Table 1 Appropriate characteristics of a skin scaffold
Characteristics Value
Mechanical properties Young’s modulus 4.5–25 MPa
Tensile strength 5–40 MPa
Elongation‑to‑break 35–120%
Physicochemical properties Porosity 60–90%
Surface wettability (water contact angle) 30–70º
water uptake ability 100–800%
Water vapor transmission rate 2000–2500 g/m2/day
Degradation rate and release profile N/A
Biological properties Albumin adsorption 250–400 μg/mL/day
Cell viability N/A
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The incorporation of ZnO-NPs in scaffolds is a promising 
approach for skin tissue engineering applications. PCL/
ZnO-NPs electrospun membrane was fabricated and 
characterized by Augustine et  al. Increased proliferation 
of dermal fibroblast cells and upregulated expression of 
FGF2 and VEGF-A were reported. The results showed the 
potential of the electrospun membrane for vascular regen-
eration in wound healing [106].
The angiogenic properties of cerium oxide nanoparti-
cles  (CeO2-NPs) have been investigated in several stud-
ies. One of the most important investigations is a study 
by Das et  al. They have demonstrated that  CeO2-NPs 
stimulate pro-angiogenesis, depending on surface val-
ance states. In  vitro studies showed the formation of 
tube structures in the presence of  CeO2-NPs. Vascular 
sprouting was the main result of in vivo studies to con-
firm the angiogenic activity of  CeO2-NPs. The main 
causes of angiogenesis induction were stated to be sta-
bilization of HIF-1α in endothelial cells and altered gene 
regulation [107]. The size of the  CeO2-NPs and the ratio 
of  Ce3+/Ce4+ are the parameters that could affect the 
angiogenic properties of the nanoparticles [108]. Another 
study demonstrated increased proliferation of endothe-
lial cells, fibroblasts and keratinocytes in the presence of 
low concentrations of  CeO2-NPs [109].  CeO2-NPs could 
be incorporated into polymeric scaffolds to be used as an 
angiogenic structure in tissue engineering. PCL/CeO2-
NP nanocomposite membrane has been shown to be 
capable of promoting angiogenesis following subcutane-
ous implantation in rats due to the stability of HIF-1α 
and increased expression of VEGF [110].
Gold nanoparticles (Au-NPs) are commonly used in 
medical applications due to their unique physico-chemical 
properties. Au-NPs can scavenge reactive oxygen species 
(ROS) through antioxidant activity [111]. High surface-to-
volume ratio of nanoparticles, make them more efficient. 
Using Au-NPs in photobiomodulation-based therapy 
accelerates the process of wound healing by improving 
angiogenesis as well as the proliferation of epithelial cells 
and the formation of collagen [112]. A study by Kim et al. 
showed that hydrocolloid membranes coated with chemi-
cally stabilized Au-NPs could be used for wound healing 
applications. Up-regulated expression of the ANGPT-1, 
ANGPT-2, VEGF and collagen genes confirmed the angio-
genic properties of these stabilized nanoparticles [113]. 
Another approach is to use surface engineered Au-NPs 
as a delivery system to deliver angiogenic factors such as 
VEGF, as reported by Chen et al. [114].
Bioactive glasses (BGs)
BG is a series of specially designed silica-based glasses 
where the 3D  SiO2 network is modified by the addition 
of CaO,  Na2O and  P2O5 [115]. BGs were first introduced 
in 1969 and described as a group of reactive biomateri-
als capable of bonding to mineralized bone tissue under 
physiological conditions. The first biomedical applica-
tion of BGs was in the form of solid pieces for small bone 
replacements in middle ear surgery [116]. The most com-
mon BG is called 45S5, consisting of 45 wt %  SiO2, 24.5 
wt % CaO, 24.5 wt %  Na2O, and 6.0 wt %  P2O5. By mix-
ing the different ratios of these four oxides, different BGs 
have been produced to enhance their inherent properties; 
additional oxides may also be used to improve specific 
therapeutic actions [115]. In recent years, BGs have been 
widely investigated for potential applications in the fields 
of regenerative medicine and tissue engineering due to 
their ability to increase angiogenesis and osteogenesis 
[117, 118]. BGs have attracted a great deal of interest, 
as their ion dissolution products have been identified to 
improve angiogenesis, which plays a key role in wound 
healing (Fig. 4).
BG-NPs have shown more advantages than conven-
tional BGs, such as better biocompatibility, faster disso-
lution of ions, higher specific surface area, increased cell 
attachment, etc. BG-NPs are known as angiogenic nano-
biomaterials and recent interest in BG-NPs increased in 
tissue engineering due to the dependence of accelerated 
wound healing on angiogenic materials [126, 127]. As the 
interest in BG-NPs increased, different methods of syn-
thesis were developed. Gas phase (flame spray), micro-
emulsion techniques, laser spinning, and sol–gel are the 
current BG–NP synthesis methods. The sol–gel method 
is the most common. BGs synthesized by the sol–gel 
method have an inherent mesoporous structure with a 
pore size of approximately 4–60 nm, which allows growth 
factors and drugs to be placed in nano-sized pores and 
then released locally in a controlled manner [128].
Some metal ions have been shown to increase angio-
genesis by affecting key factors. The optional addition of 
these ions (e.g.  Mg2+,  Cu2+) to the BG-NPs could there-
fore promote the angiogenic properties of the particles 
and make them interesting to be used to accelerate the 
healing process (Table  2). In addition, ion-loaded BG-
NPs could be incorporated into other polymeric bio-
materials to improve their mechanical and biological 
properties. Such nanocomposite scaffolds have shown a 
good potential for wound healing and skin tissue engi-
neering applications [87, 129].
Biodegradable tiny cotton-candy borate BG (Mo-
Sci Corp., Rolla, MO, USA), imitating the micro-
structure of a fibrin clot, was reported to improve 
wound healing in both animals and human patients. 
These BG nanofibers (basic 13-93B3 composition: 
 53B2O3–6Na2O–12K2O–5MgO–20CaO–4P2O5 wt  %), 
trade-named as DermaFuse™/Mirragen™, help impres-
sively the healing of long-term venous stasis ulcers in 
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diabetic patients, who were irresponsive conventional 
treatment [130]. Studies carried out in a rat subcutane-
ous model showed that the angiogenetic effect can be 
further accelerated by doping the BG with small amounts 
of copper that is locally released into the biological envi-
ronment [131].
Carbon nanotubes (CNTs)
CNTs are cylindrical molecules composed of single-
layer carbon atom rolled-up sheets. CNTs have two 
single-walled and multi-walled forms. Single-walled 
carbon nanotubes (SWCNTs) have a diameter of 
approximately 1 nm or less. Multi-walled carbon nano-
tubes (MWCNTs) consist of several concentric nano-
tubes with a total diameter of more than 100 nm. The 
length of these structures is variable and may reach 
several micrometers or even millimeters depending 
on their use [142]. Nanostructure, large specific sur-
face area, electrical conductivity and good mechani-
cal properties make CNTs suitable for biomedical 
applications such as biosensors, drug and gene deliv-
ery systems, tissue engineering and regenerative 
Fig. 4 Ions release from incorporated mesoporous BG during the wound healing process [119–125]
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medicine [86, 143, 144]. It has been shown that VEGF 
and matrix metalloprotein-9 (MMP-9), which are 
involved in angiogenesis and tissue remodeling, could 
be released by stimulated macrophages exposed to 
CNTs [139]. CNTs could be modified in order to be 
functionalized for angiogenesis regulation. Polyam-
ine-coated CNTs were used as a micro-RNA delivery 
system to regulate angiogenesis by targeting endothe-
lial cells [145]. In another study, Liu et  al. treated the 
surface of CNTs with plasma. Then, VEGF was loaded 
onto the nanotubes to provide a new system with con-
trolled release of VEGF. In the next step, porcine small 
intestinal submucosa was exposed to these modified 
VEGF-loaded CNTs. Results showed a statistically sig-
nificant increase in angiogenesis during repair of the 
abdominal wall defect [146]. Using CNTs in the struc-
ture of polymeric scaffolds could also provide a suit-
able mechanical strength and give them biological 
advantages as studied by Lalwani et al. [147].
Graphene‑based nanomaterials
Graphene is a monolayer of carbon atoms bound in a hon-
eycomb-like lattice with a two-dimensional  sp2 structure. 
Such a unique structure is responsible for many specific 
properties of graphene, such as excellent mechanical prop-
erties, large surface area and exceptional thermal conduc-
tivity [148]. The potential of graphene was first explored 
for use in energy storage and sensors. The first biomedical 
use of graphene dates back to 2008 when it was introduced 
as a drug delivery carrier [149]. Since then, graphene has 
been considered as a potent biomaterial to be used in 
biomedical research. Biosensors, nanomedicine, delivery 
systems, imaging, diagnostics, regenerative medicine, bio-
medical and tissue engineering are the biological fields in 
which graphene-based materials are used [150–152].
Graphene oxide is one of the graphene-based mate-
rials with angiogenic properties. Graphene oxide is a 
unique graphene that is chemically modified and con-
tains oxygen-containing functional groups (such as 
Table 2 Angiogenic ions incorporated in BG-NPs [127, 132–141]
HUVECs human umblical vein endothelial cells, CAM chorioallantoic membrane, hBMSCs human bone marrow stem cells, HUCPVCs human umbilical cord perivascular 
cells, HAECs human amniotic epithelial cells
Angiogenic Element BG Type In vitro (cell type)/in vivo (animal model) Results Refs.
Calcium silicate 45S5 BG In vitro (HUVECs) Increased expression of VEGF, bFGF, KDR, 
bFGFR and NOS3 genes in HUVECs
[132]
Boron 45S5 BG In vivo (CAM of quail embryos) Increased expression of integrin αvβ3, 
Increased number of blood vessels
[133]
Copper Borate BG In vitro (hBMSCs)/in vivo (rat with calvarial 
defects)
Increased in vitro proliferation of hBMSCs, For‑
mation of new blood vessels was confirmed 
by IHC staining for CD31
[134]
Cobalt and Strontium 45S5 BG In vitro (HUCPVCs)/in vivo (defect in the distal 
femur of rabbit animal model)
Increased expression level of VEGF gene in the 
HUCPVCs, formation of new blood vessels 
was confirmed by IHC staining for VEGF 
protein
[135]
Silicon S53P4 BG In vitro (Human CD‐18CO fibroblasts) Increased proliferation of fibroblast cells, 
Increased secretion of VEGF, stimulation of 
neovascularization
[136]
Magnesium Silicate BG In vitro (HAECs)/in vivo (rabbit bone defect) Increased proliferation of HAECs, HAECs align‑
ment and exhibition of branch nodes that 
is a phenomenon of the primary stage of 
angiogenesis, Increased NOS3 gene expres‑
sion, Promoted angiogenesis in the defect 
area
[137]
Europium Mesoporous BG 45S5 In vitro (HUVECs)/in vivo (Mice with full‑thick‑
ness wound)
Upregulated angiogenesis‑related genes 
(MMP9, VEGFR1/2, CD31 and PDGFR α/β) of 
HUVECs, blood vessel formation, collagen 
deposition and re‑epithelialization at chronic 
skin wound sites
[138]
Niobium 45S5 BG In vitro (ST‑2 bone marrow stromal cells) Improved proliferation of bone marrow stro‑
mal cells, significant increase in VEGF release
[139]
Strontium Borate BG In vitro (hBMSCs)/in vivo (Critical‑sized rabbit 
femoral condyle defect model)
Increased proliferation of hBMSCs, Upregu‑
lated expression of genes associated with 
angiogenesis and osteogenesis, such as 
VEGF, RUNX2, BMP‑2, and osteopontin
[140]
Strontium and Copper 45S5 BG In vitro (hBMSCs, HUVECS) Differentiation of hBMSCs to vascular endothe‑
lial cells, formation of tubular and nodal 
networks of HUVECs
[127]
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carboxylic acid, alcohol, hydroxyl, epoxide and carbonyl) 
in its structure with approximately three to one carbon/
oxygen ratio. Over the last decade, graphene oxide has 
been widely used in biomedical applications [153, 154]. 
Angiogenic properties of graphene were investigated in a 
study conducted by Norahan et al., which demonstrated 
improved angiogenesis due to the use of a cardiac patch 
composed of collagen/graphene [155]. Appropriate con-
centrations of graphene oxide and its reduced form have 
been shown to enhance angiogenesis by induction of 
ROS production. Concentrations less than 100  ng have 
been reported to stimulate angiogenesis. Higher con-
centrations induce cell toxicity and inhibit angiogenesis 
[156, 157]. Qian et  al. developed a 3D graphene oxide/
PCL composite scaffold to regenerate injured sciatic 
nerves in  vivo by promoting angiogenesis. Results con-
firmed upregulation of the PI3K/Akt/eNOS/VEGF sign-
aling pathway compared to the control group (treated 
with PCL scaffold) which demonstrated the enhanced 
angiogenesis due to the presence of graphene oxide [158]. 
Nyambat et  al. produced an adipose stem cell derived 
ECM-nano graphene oxide composite sponge for skin 
regeneration. The results showed the potential of the bio-
compatible angiogenic scaffold for skin tissue engineer-
ing applications [159].
Europium hydroxide
Lanthanides are widely used elements in scientific 
research that have attracted researchers in immunoassay 
and biological imaging studies in recent years. Europium 
is the most reactive lanthanide that has been studied as 
a potent element to enhance angiogenesis in biologi-
cal investigations in recent decades [160]. In 2008, Patra 
et  al. studied the interaction between europium (III) 
hydroxide nanorods with human umbilical vein endothe-
lial cells (HUVECs) to evaluate pro‐angiogenic properties 
of these nanorods. The results showed the internalization 
of the nanorods to the HUVECs. Chick chorio-allantoic 
membrane assay of HUVECS treated with the europium 
(III) hydroxide nanorods demonstrated vascular forma-
tion due to increased angiogenesis [161]. The molecu-
lar mechanism of angiogenesis induced by europium 
hydroxide nanorods was first suggested by Nethi et  al. 
in 2015. Europium hydroxide nanorods has been shown 
to induce  H2O2 production that activates the enzyme 
nitric oxide synthase 3 (NOS3) which has a protective 
function in the cardiovascular system. NOS3 triggers 
the PI3K/Akt signaling pathway to increase nitric oxide 
(NO) secretion, leading to angiogenesis [156]. The mech-
anism of angiogenesis induced by europium hydroxide 
nanorods is presented in Fig. 5.
The results obtained from such studies introduce euro-
pium oxide nanorods as a potent angiogenic material for 
use in tissue engineering applications. Europium oxide 
nanorods/PCL electrospun membrane has been shown 
to increase the rate of angiogenesis in chicken embryos 
compared to PCL electrospun membrane. The angio-
genic activity was attributed to the ability of the scaffold 
to activate the VEGFR2/Akt signaling pathway due to the 
presence of europium oxide nanorods [162].
Skin tissue engineering
New nanomaterial-based treatments for skin wounds have 
been developed in recent years. Several in  vitro (stud-
ies conducted on endothelial cells such as HUVECs) and 
in vivo (rats, mice, rabbits and guinea pig models) studies 
have confirmed the efficacy of nanocomposite scaffolds 
on angiogenesis [16, 163]. Nanoparticles are widely used 
as an effective part of composite scaffolds to accelerate 
the healing process of chronic wounds through their vari-
ous properties, such as angiogenic, anti-inflammatory and 
anti-bacterial properties [164]. Many clinical trials have 
been developed for skin regeneration based on nanopar-
ticles, but  Acticoat® is the only US FDA approved nano-
particle-based skin product. The wound dressing contains 
silver nanoparticles that could be released slowly dur-
ing the healing process. The antibacterial properties of 
these nanoparticles minimize the need for several wound 
Fig. 5 Mechanism of angiogenesis induced by europium hydroxide 
nanorods
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dressings to be used during the healing of chronic wounds 
and also reduce the inflammatory response [165]. There 
is still no FDA-approved skin product with angiogenic 
nanomaterials in its structure, but the emerging number 
of related studies shows the potential of these nanobio-
materials for skin regeneration. The development of new 
techniques and methods facilitated the use of angiogenic 
factors, materials and nanoparticles in engineered struc-
tures and delivery systems [166]. However, a wide range of 
biomaterials have been characterized and used as compos-
ite and nanocomposite skin scaffolds, but there are many 
biological, engineering and clinical challenges that need to 
be considered. A summary of some of these challenges is 
presented in Table 3.
(Hydro-) gels are promising materials with great poten-
tial for development in the field of biology and medicine. 
They are widely used in wound healing and skin tis-
sue engineering applications in a variety of ways [171]. 
(Hydro-) gel-based scaffolds usually exhibit appropri-
ate biological properties despite their mechanical prop-
erties. The formation of (hydro-) gels with appropriate 
mechanical properties is challenging due to their natural 
low mechanical strength. The incorporation of nanoma-
terials is one of the feasible solutions for improving their 
stiffness. On the other hand, the structural network of 
(hydro-) gels provides an adhesive environment for nano-
structures to present their biological properties more effi-
ciently [172, 173]. The incorporation of nanostructures 
gives hydrogels specific properties that improve wound 
healing. Hydrogels incorporated with ZnO-NPs have 
been shown to support angiogenesis as studied by Ahtzaz 
et  al. [174]. Adding graphene oxide-based nanomateri-
als to hydrogels can enhance cell attachment to improve 
angiogenesis in tissue engineering applications [175]. The 
incorporation of silicate BG-NPs into hydrogels supports 
the bonding of biomaterials and wounded tissues [87]. In 
a recent study by Li et  al., silica-based nanocomposites 
hydrogel scaffolds were fabricated for enhancing angio-
genesis to accelerate diabetic wound healing. Polyeth-
ylene glycol diacrylate (PEGDA) was used as the main 
network of the nanocomposite scaffold. Copper-contain-
ing BG-NPs and sodium alginate were added to induce 
angiogenesis. The in  vivo results of the study showed 
increased number of vessels, high levels of blood flow 
volume, and accelerated wound healing (Fig. 6) [176].
Incorporated (hydro-) gels are used in tissue engineer-
ing techniques to produce a wide range of skin scaffolds 
with angiogenic properties. Nowadays, three dimensional 
(3D) bio-printing of skin is a popular research area. Bio-
material selection is one of the key steps in this tech-
nique and the most common type of biomaterial used 
is biopolymer-based hydrogels. There is a wide range of 
natural, synthetic and composite biopolymers available 
for 3D skin bio-printing, which can be selected based on 
the type of printing process [177]. Both of the natural and 
synthetic biopolymers have certain limitations. Despite 
having the greatest advantage of imitating ECM, natural 
biopolymers exhibit poor mechanical properties. On the 
other hand, synthetic biopolymers have the advantage of 
excellent mechanical properties, but their microstruc-
tures are very different from the ECM of native tissue. 
Researchers therefore prefer to produce composite scaf-
folds, which have both natural and synthetic polymer 
components, in order to combine the advantages of both 
and overcome limitations [178]. Gelatin, chitosan, colla-
gen and silk fibroin are the most common natural biopol-
ymers used in printed skin scaffolds and the synthetic 
biopolymers are PCL, polylactic acid (PLA), and PLGA. 
Composite scaffolds are produced by a combination of at 
least one of each group [179–181].
Some basic requirements for bio-printing, summarized 
in Table 4, should be considered in order to achieve the 
optimal properties of skin scaffolds.
More than 200 polymers could produce nano- or micro-
scale fibers using the electrospinning technique. All of 
these polymers are not proper for biological applications. 
Biocompatibility is the most important factor that deter-
mines whether a material is suitable for biomedical appli-
cations or not [188]. After identifying the biocompatibility 
of a polymer, other features that make a polymeric con-
struct suitable for regeneration of a target tissue should be 
considered. Mechanical properties and degradation rate 
are important factors for producing an engineered skin 
scaffold [189]. Electrospun polymers provide a wide range 
of skin scaffolds for chronic wound healing applications. 
The most significant advantage of these types of nanofi-
brous scaffolds is the high surface/volume ratio that facili-
tates cell adhesion during the healing process. Biopolymers 
are used individually or in combination with other biopol-
ymers [190]. Chitosan, alginate, chondroitin, collagen, 
Table 3 Biological, engineering and clinical challenges in skin tissue engineering [167–170]
Biological Challenges Engineering Challenges Clinical Challenges
Selection of a suitable cell source Selection of biocompatible material Adaptation of the scaffold to the surrounding tissue
Repeatable cell differentiation condition Optimal mechanical properties Appropriate volume and shape of the regenerated tissue
Selection of growth factors, biomolecules 
and bio‑active agents
Repeatable scaffold fabrication condition Post‑surgical nutrition and oxygenation
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gelatin, fibrin, keratin and silk fibroin are the most com-
mon natural polymers used single or blended to provide 
the electrospun scaffolds for skin tissue engineering [191, 
192]. PCL, PLGA, poly (3-hydroxybutyrate-co-3-hydroxy-
valerate) (PHBV), poly (etherurethane urea) (PEUU) and 
poly (glycerol sebacate) (PGS), are the examples of syn-
thetic polymers used for regeneration of damaged skin tis-
sue [169, 193]. The incorporation of nanostructures into 
these nano-/micro fibers is a common approach to provid-
ing controlled-release functional systems.
Porous polymeric sponges, in combination with 
nanobiomaterials and growth factor, can provide an 
appropriate microenvironment for cells homing, migra-
tion and differentiation. Porous scaffolds are prepared 
by different techniques such as freeze drying, particle 
leaching method and solid freeform fabrication. A 
wide range of natural and synthetic polymers are used 
to fabricate such porous scaffolds. Freeze drying is 
one of the most developed method to fabricate porous 
sponges. In this method, pores size could be controlled 
by changing amount of organic solvents and freezing 
temperature. Gas-foaming and solvent casting/particle 
leaching also give a suitable control over pores shapes 
and sizes. Incorporating of organic or inorganic fillers 
during scaffold preparation process is an efficient way 
to improve mechanical properties of composite scaf-
folds [194, 195].
Table 5 summarizes the application of engineered skin 
scaffolds incorporated with growth factors or nanobio-
materials to induce angiogenesis in wound healing.
Fig. 6 Effect of hydrogel scaffolds on diabetic wound healing. a Construction of diabetic wound model in ICR mice; b Wound healing process 
during 21 days treatment by different scaffolds (PA: PEGDA + sodium alginate, PAB: PEGDA + sodium alginate + BG‑NPs, PABC: PEGDA + sodium 
alginate + copper‑containing BG‑NPs), DM: Diabetes mellitus wound was used as a control; c Wound closure rates at day 7, 14 and 21. (*p < 0.05 and 
**p < 0.01.). Reprinted with Permission from [176]
Table 4 Suitable properties of 3D bio-printing hydrogels [182–187]
Biocompatibility Printability Morphological properties Mechanical properties Physicochemical properties
Cell toxicity Rheological properties and viscosity Porosity percentage Young’s modulus Wettability
Blood toxicity Sol–gel transition in response to 
temperature change
Pore size and shape Strength Degradation rate
Immunogenicity Transition time Micro‑/nanostructure Elasticity Swelling
Protein adsorption Shear thinning Stiffness Water vapor transition rate
Cell attachment Elongation to break
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Conclusion
Skin as an integral organ is the body’s first barrier against 
external pathogens. Any serious damage to the skin could 
have an impact on human health and quality of life. The 
management of the pathological conditions of this organ 
seems to be a critical issue in order to reduce the eco-
nomic pressure on the medical system and patients. In 
recent decades, different approaches have been devel-
oped to improve the rate and quality of chronic wound 
healing. What is evident is the essential role of angio-
genesis in the regeneration of damaged skin. Common 
approaches for improving angiogenesis are based on 
cell, protein and gene delivery systems. Recent progress 
in nanobiotechnology has significantly improved poten-
tial applications in delivery systems. Developed meth-
ods in material science and tissue engineering provide 
an opportunity to use angiogenic nanobiomaterials in 
the design of engineering structures to provide complex, 
sustained release systems. In this paper, we reviewed the 
different uses of angiogenic nanobiomaterials in chronic 
wound healing and skin tissue engineering applications 
based on previous studies.
As mentioned above, the generation of a functional vas-
cular network is one of the major challenges in the regen-
eration of damaged skin. For this purpose, the quality of 
the regenerated vascular network is more important than 
quantity. In other words, functional blood perfusion over 
the vascular network is the criterion, not just the number 
of regenerated vessels. The importance of the organiza-
tion and maturation of the vascular structure is therefore 
clear. On the other hand, over-stimulating angiogenesis 
leads to the generation of many unorganized vessels with 
poor blood perfusion and inefficient performance. The 
organization of vascular structures is not only a factor 
that determines the quality of the regenerated tissue, but 
it seems to be a basic principle. Incorporation of bioac-
tive molecules and nanobiomaterials with angiogenic 
properties is a growing strategy that is highly useful for 
improving tissue regeneration by improving angiogenesis 
and vascularization, but achieving tissue with normal and 
functional vascular structures remains a challenge.
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